CXCL14

Across TCGA pan-cancer cohorts, CXCL14 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CXCL14 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CXCL14 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CXCL14 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

GBM, HNSC, and PDAC are the cancer types where CXCL14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.332	0.648	.016	5	view →
HNSC	DFS	Tertile	III,IV	1.000	0.911	.036	5	view →
PDAC	OS	Quartile	II,III,IV	1.000	0.685	.007	5	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.386	.027	4	view →
LUAD	OS	Median	All	0.649	0.954	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CXCL14–GBM (OS)

Open the GBM breakdown →